Roche's I/O 2.0 dreams take a hit as TIG­IT in­hibitor fails PhI­II

In a dis­ap­point­ing set­back for one of the bright­est can­di­dates in the next-gen check­point race, tiragolum­ab — Roche’s “break­through” TIG­IT drug — has failed a Phase III …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER